Skip to content
Screener

EPS (Diluted) at other companies

Insulet logo
InsuletPODD
$1.37+328%
Medtronic logo
MedtronicMDT
$0.97+18.3%
Beta Bionics logo
Beta BionicsBBNX
-$0.53-35.9%
Embecta Corp. logo
Embecta Corp.EMBC
$0.36-53.8%
AdaptHealth logo
AdaptHealthAHCO
-$0.12-140%
Mannkind logo
MannkindMNKD
-$0.06

Other financials

Income statement

See full
Revenue$254.6M+5.8%
Gross profit$144.8M+15.0%
Operating income-$13.8M+73.4%
Net income-$21.2M+59.6%

Balance sheet

See full
Cash & equivalents$62.8M-2.0%
Total debt$739.3M+64.6%
Total equity$130.4M-2.2%
Total assets$1.2B+31.8%

Cash flow

See full
Operating cash flow-$34.6M-265%
CapEx$4.1M-34.7%
Free cash flow-$38.7M-146%

Valuation

See full
Market cap$1.29B+34.3%
Enterprise value$1.96B+46.2%
P/S1.2×+0.3×

Profitability

See full
Gross margin56%+3.5pp
Operating margin-4.4%-1.9pp
Net margin-6.1%-2.5pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-48%-17.5pp
Debt / equity5.7×+2.3×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001438133-26-000125
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net loss$(21,168)$(52,400)$(41,561)$(182,956)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments$(692)$(98)$(1,719)$325
Unrealized gain (loss) on cash flow hedges716(612)2,418(612)
Foreign currency translation gains1,3354,3801115,979
Comprehensive loss$(19,809)$(48,730)$(40,751)$(177,264)
Net loss per share - basic and diluted$(0.31)$(0.78)$(0.60)$(2.74)
Weighted average shares used to compute basic and diluted net loss per share69,01167,05068,70666,729

Item 1. Financial Statements.

FAQ

What is Tandem Diabetes Care's EPS (diluted)?
Tandem Diabetes Care (TNDM) reported EPS (diluted) of -$0.31 in Q2 2026.
How has Tandem Diabetes Care's EPS (diluted) changed year-over-year?
Tandem Diabetes Care's EPS (diluted) increased by 60.3% year-over-year, from -$0.78 to -$0.31.
What is the long-term trend for Tandem Diabetes Care's EPS (diluted)?
Over 4 years (2021 to 2025), Tandem Diabetes Care's EPS (diluted) has grown at a 91.1% compound annual growth rate (CAGR), from $0.23 to -$3.07.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Tandem Diabetes Care's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude